FRLN - Gene Therapy Player Freeline Therapeutics Goes Private In $28M Deal | Benzinga
London-listed Syncona Ltd has agreed to acquire Freeline Therapeutics Holdings plc (NASDAQ: FRLN) in an all-cash transaction for $6.50 per American Depositary Share.
This price values Freeline's entire issued share capital at approximately $28.3 million and represents a 51% premium over the closing price before the announcement of Syncona's initial proposal on October 18.
The acquisition is expected to close in the first quarter of 2024.
If completed, the ...